ERBB2 and adenocarcinoma: We observed HER2 expression in 123 (57.4%) adenocarcinomas which were composed of 1+ (negative) 62 cases; 2+ (equivocal) 38 cases (Figure 2A); and 3+ (positive) 23 cases (Figure 2B).